STUDY PROTOCOL





The efficacy and safety of acupuncture and nicotine replacement therapy for smoking cessation: study protocol for a randomized controlled trial

Qingsheng Wang^{1,2†}, Runjing Dai^{3†}, Hailiang Zhang³, Xiaomei Jiang⁴, Xiaojing Ma⁴, Xiangrong Zhang⁵, Shisan Bao^{3*}, Dong Ren^{4*} and Jingchun Fan^{3*}[®]

Abstract

Introduction: Tobacco hazard is one of the most serious public health problems, accounting for up to 6 million deaths worldwide p.a. We aim to determine the efficacy and safety of acupuncture and/or nicotine replacement therapy on smoking cessation.

Methods: We will recruit 96 participants who are willing to quit smoking by acupuncture and/or nicotine replacement therapy in Chengguan, Xigu and Heping Districts, Lanzhou city, for multicenter randomized, double-blind, double-dummy controlled clinical trial. Following obtained the informed consent forms, all eligible participants will be randomly divided into 4 groups: (1) acupuncture combined with nicotine patch, (2) acupuncture combined with sham nicotine patch, (3) sham acupuncture combined with nicotine patch, and (4) sham acupuncture combined with sham nicotine patch. These participants will be treated with different intervention modalities for 8 weeks and then will be followed-up for 8 weeks. The SPSS 26.0 software will be applied to analyze the clinical effects and adverse reactions of different intervention measures for smoking cessation.

Discussion: This trial is a prospective, pragmatic, randomized, multicenter trial study protocol. The outcomes will illustrate the efficacy and safety of acupuncture and/or nicotine patches for smoking cessation. Provide smokers with a superior smoking cessation program.

Trial registration: Chinese Clinical Trial Registry ChiCTR2100042912. Registered on January 31, 2021.

Keywords: Acupuncture, Nicotine replacement therapy, Smoking cessation

[†]Qingsheng Wang and Runjing Dai contributed equally to this work.

*Correspondence: profbao@hotmail.com; lzshld@163.com; fan_jc@126.com

³ School of Public Health, Laboratory and Simulation Training Center, Center for Evidence-Based Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, People's Republic of China

⁴ Psychosomatic and Sleep Medicine, Gansu Gem Flower Hospital,

Lanzhou, Gansu 730060, People's Republic of China Full list of author information is available at the end of the article

Introduction

Tobacco dependence is a chronic addictive disease, encoded as F17.21 in the International Classification of Diseases (ICD-10) [1]. Because cigarettes contain more than 70 carcinogens [2], long-term smokers can cause multi-organ and tissue damage, e.g., respiratory, cardiovascular, and neuromuscular diseases, and even death [3]. Quitting smoking is one of the most effective approaches to improve health condition and save lives. The benefit of reducing/quitting smoke is evidenced in improving the

© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

quality of life via decreasing the mortality and morbidity of cancer and cardiovascular diseases [4, 5]. Although there are 40% smokers who are/were willing to quit, only 8% are quitting successfully for multiple reasons [6]. Therefore, it becomes critical important to explore the effective approach to assist these remind unsuccessful quitting smokers to achieve their goal.

Nicotine replacement therapy (NRT), considered the basic treatment for smoking cessation, is the main pharmacological smoking cessation modality recommended by WHO [7]. Currently, NRT includes nicotine patches, nicotine gum, nicotine nasal sprays, and nicotine inhalers. Although nicotine patches are available for a long time within the most effective in smoking quitting [8, 9], the safety of nicotine patches is debated, partially is due to its adverse reactions, e.g., dizziness, headache, and nausea [10]. Acupuncture is a relatively common approach for smoking cessation over the past decades [11] with benefit of short-term abstinence, safety, and economic costs. During smoking cessation acupuncture significantly improves withdrawal symptoms, including upset, irritability, anxiety, and impatience experienced. However, the precise role of acupuncture for smoking cessation requires further clarification [12, 13]. Hyun S et al. demonstrate that NRT and behavioral counseling combined with auricular acupuncture are safer and more effective than traditional therapy alone [14]. However, it is still controversial about the efficacy of smoking cessation in acupuncture, NRT, and other interventions in clinical trials or related meta-analysis studies [15, 16], which remains to be validated.

It is reported that combined approach is more effective than a single intervention in improving the successful rate of smoking cessation. Therefore, this trial will use a double-blind and double-dummy randomized controlled trial, to explore the efficacy and safety of acupuncture and/or nicotine patch with placebo on smoking cessation, so as to enrich and optimize smoking cessation programs and provide effective smoking cessation methods with lower relapse rates for smokers.

Methods

Objectives

The objective is to explore the effect and safety of different interventional approaches, e.g., acupuncture with or without nicotine patch, nicotine patch, and placebo for smoking cessation.

Study design

This study will be used a randomized, controlled, double-blind, double-dummy, multiple-center experimental design. We will follow the ethical principles of the Declaration of Helsinki and adhere to the principles Page 2 of 8

of good clinical practice. The study is registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2100042912) on January 31, 2021. The diagram is illustrated that the different phases of the study (Fig. 1 and Table 1). The Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) checklist is provided as Additional file 1 [17].

Eligibility criteria of the participants

Diagnostic criteria

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) prepared by the American Psychiatric Association, Diagnostic Criteria for Nicotine Dependence 292.0:

- 1. Daily use of nicotine for at least 3 weeks
- 2. More than 4 of the symptoms that occur within 24h after stopping or reducing smoking: dysthymia or depression, insomnia, irritability, anger, anxiety, difficulty concentrating, restlessness, slow heart rate, and increased appetite or weight gain
- 3. Clinically significant distress due to the above symptoms or functional deficits in social, occupational, and other important aspects
- 4. These symptoms are not due to a physical condition and cannot be attributed to any other mental disorder

Inclusion criteria

- 1. Meets diagnostic criteria for smoking
- 2. Smokers who voluntarily quitted smoking
- 3. \geq 16 years
- 4. Informed consent

Exclusion criteria

- 1. Participants with severe heart, brain, lung related system diseases and diabetes
- 2. Participants who have received other relevant smoking cessation treatment within half a month
- 3. Allergic to nicotine patch or acupuncture

Dropout criteria

- 1. Occurrence of serious adverse events
- 2. The participants withdraw spontaneously
- 3. Participants develop serious diseases during treatment



Sample size calculation

We will use the calculation formula of sample size of enumeration data in a completely random design, as describe previously. The PASS software will be used for calculation. The formula is listed as follow:

$$N = \frac{\left[Z_{\alpha}\sqrt{2p(1-p)} + Z_{\beta}\sqrt{p_1(1-p_1) + p_2(1-p_2)}\right]^2}{(p_1 - p_2)^2}$$

 $\alpha = 0.05$ will be set up as the level of test, and the test power is 90%. The withdrawal rates of acupuncture (p_1) and placebo (p_2) will be 56% [18] and 9.1% [19], respectively; p is the mean of p_1 and p_2 . The PASS 26.0 software will be used to calculate that the sample size required for each group for ≥ 18 cases. Considering 30% loss to follow-up rate, the sample size per group will be 24 cases. Consequently, the total number of the participants will be 96, based on 24 case per group in the four groups.

Randomization

A total of 96 eligible participants will be recruited from Chengguan, Xigu and Heping Districts, Lanzhou City, Gansu Province, by posters and the most popular and ubiquitous Chinese form of social media, WeChat.

- 1) Sequence generation: A series of consecutive numbers (from 1 to 96) will be generated prior to the recruitment, and computer software (Microsoft Excel 2016) will be used to randomly assign each number to one of the four intervention groups (1: acupuncture combined with nicotine patch group (ACNP), 2: acupuncture combined with sham nicotine patch group (ACSNP), 3: sham acupuncture combined with nicotine patch group (SACNP), and 4: sham acupuncture combined with sham nicotine patch group (SACSNP)
- Allocation concealment mechanism: All will be performed in the double blind fashion. This randomization sequence will be inserted into sequentially num-

	STUDY PERIOD							
TIMEPOINT**	Enrolment	Allocation 2021.11	Post-allocation				Close-out	
	2021.8		2021.12	2022.1	2022.3	2022.4	2021.5	2022.7
ENROLMENT:								
Eligibility screen	•	•						
Informed consent	•							
(List other procedures)	×	×						
Allocation		•	•					
INTERVENTIONS:								
(Intervention A)				•		•		
(Intervention B)				•		•		
(Intervention C)				•		•		
(Intervention D)				•		•		
ASSESSMENTS:								
(List baseline variables)	•		•					
(List outcome variables)					•		•	×
(List other data variables)			×	×	×	×	×	×

Table 1 The schedule of enrolment, interventions, and assessments

bered, opaque, sealed envelopes (to ensure allocation is concealed from assessors). These envelopes will be opened by the acupuncturist treating the patient

Recruitment

We will recruit participants from three hospitals separately, involving in the smoking cessation based on the distribution of participants. Such recruitment will be broadcasted using a few approaches, including posters and the most popular and ubiquitous Chinese form of social media, WeChat, to establish contacts with various ethnic community, university, and business groups, and conducted community-based smoking cessation programs.

Blinding

In this study, a randomized, controlled, double-blind, double-dummy, multi-center experimental design method will be adopted. In view of the particularity of acupuncture manipulation, it is difficult to blind the practitioners of the study. Thus, we can only blind the participants and the data collectors. The specific operation process is as follows: prior to the study, the participants will sign the informed consent, and each participant will be informed that both acupuncture and patch treatment methods would be adopted. The research group will select two groups of acupuncture points (Fig. 2, Fig. 3), so the locations of each acupuncture point may be different, but we will not inform the specific names of the acupuncture points and their effects. Because placebo patches are the exact size and



shape of the patch that has already been purchased, the participants will be masked the intervention received all the time. In addition, in our data collection process, specialized data collectors send questionnaires to the research objects in the form of "Questionnaire Star," and the data collection is completed through the network. To ensure the correct application of blindness in this study, these participants will be not aware of the grouping of the research objects.

Assignment of interventions (for controlled trials) allocation

Acupuncture or sham acupuncture

Acupuncture points Baihui, Lieque, Hegu, Shenmen, and Sweet points (Fig. 2) [12]. Participants will be placed in a supine position with adequate exposure of the selected



acupoints and disinfection with 75% medical alcohol. For Hegu acupoint, 0.25×40 mm acupuncture needles will be inserted downward and vertically, and a disposable 0.25 mm-25 mm acupuncture needle will be used to insert the needle 0.5 inch downward at a 15° angle to the skin at the other acupoints. All acupoints will be fixed after needles insertion, and the presence of soreness and swelling sensation in the acupoints will be used as the standard.

Acupoints on the auricle corresponding to shoulder, eye, knee, or elbow will be taken with sham acupuncture (Fig. 3) [20]. Except for the eye points, acupuncture needles of $0.18 \text{ mm} \times 13 \text{ mm}$ will be used to prick downward at a 15° angle with the skin, and the eye points will be inserted vertically into the needles and fixed.

The needle will be kept for 20 min for each time after insertion. During the period of needle retention, group 1 and group 2 will be given needle every 10 min, and a dry cotton ball will be used to press the pinhole when the needle is released. The participants will be acupunctured three times a week from week 1 to 4, and twice a week from week 5 to 8. Thus, total acupuncture time will be 8 weeks.

Nicotine or sham nicotine patches

The nicotine or sham patch will be stuck on the chest, upper arm, wrist, or thigh of each participant, ensuring the patches are kept dry and clean. The specific course and dosage are shown (Table 2).

Baseline data

We will collect basic information including age, gender, ethnicity, educational level, BMI, blood pressure, heart rate, marital history, smoking history, daily smoking amount, times of quitting, smoking status of family members, and friends in the questionnaire.

Outcomes

Primary outcome

Abstinence rate, relapse rate, and expiratory CO value will be selected as the main outcome indexes. The former two are mainly judged by the self-report of the participants at the end of treatment and follow-up, while the expiratory CO content is mainly detected by the CO detector.

 Table 2
 Duration and dosage of nicotine patch

Week 1-2	Weeks 3–4	Weeks 5–8
2 patches/day	1 patch/day	0.5 patches/day
2 patches/day		
1 patch/day		
	Week 1-2 2 patches/day 2 patches/day 1 patch/day	Week 1-2 Weeks 3-4 2 patches/day 1 patch/day 2 patches/day 1 patch/day 1 patch/day -

Secondary outcome

Secondary measures included a modified Fagerstrom test for nicotine dependence (FTND) score, a Minnesota Nicotine Withdrawal Scale (MNWS), and modified Brief Questionnaire of Smoking Urge (QSU-Brief) score. The three scores will be used to reflect the severity of nicotine dependence, withdrawal symptoms, and smoking craving of the participants. The higher scores indicate, the more severe symptoms. Each patient will be asked a questionnaire prior to the treatment and at 1, 4, and 8 weeks after the treatment. Table 3 shows the specific observation points of each index during the study.

Adverse events

Adverse events in this study included needle fainting, stagnation, bending, folding, and allergy during the use of the patch, as well as adverse reactions such as bleeding, hematoma, dizziness, fainting, residual needle sensation, tenderness, and infection during the treatment. In case of any adverse reaction, the physician will take protective measures for the subject in time and decide whether to stop the trial based on the disease condition and experience director. The study director will record the time, degree, duration, and treatment measures of the occurrence on the observation sheet and indicate the date of the report, to facilitate the later evaluation of the correlation between the occurrence and the test.

Data management and monitoring

We will collect the data by issuing questionnaires through WeChat in the form of "Questionnaire Star." To enhance the accuracy of the data and maintain the quality of the data. All the data collected will be checked and collated by two dedicated data managers and then import into the Excel. These data will be kept confidentially until the end of the trial and will not be available to anyone except for the data administrator.

Our study will start in August 2021, and the specific study stages and procedures are shown in Fig. 1 and Table 1.

Table 3 The measurement time points of v	various indicators
--	--------------------

Indicators	Before	Treatme	End of the		
	start of treatment	Week 1	Week 4	Week 8	follow-up
Abstinence rate				\checkmark	\checkmark
Relapse rate					\checkmark
Expiratory CO value	\checkmark			\checkmark	
FTND scores	\checkmark	\checkmark	\checkmark	\checkmark	
MNWS	\checkmark	\checkmark	\checkmark	\checkmark	
QSU-Brief scores	\checkmark	\checkmark	\checkmark	\checkmark	

Statistical analysis

The SPSS 26.0 software will be used for analysis. Measurement data will be expressed as $mean \pm SD$, and enumeration data will be expressed as rate. Repeated measurement analysis of variance will be used for intragroup comparison of measurement data satisfying normal distribution, and SNK (Student-Newman-Keuls) method will be used for inter-group comparison; quantitative data will be tested by χ^2 . Nonparametric tests will be used for data that do not meet the normal distribution and equal variances. $P \le 0.05$ will be considered significant. PPS (per-protocol set) will be used in the current study, and only the data will be analyzed from the participants who will perform the whole process. For those who lack follow-up data, the data of the last observation carried forward.

Participant's management system

The informed consent will be obtained to all of the participants prior to the conduct of the study. The testers will be followed up regularly and given verbal spiritual encouragement to minimize dropout.

Ancillary and post-trial care

At the end of the trial, we will provide free nicotine patch to the participants who have not achieved the cessation goal or effect until the desired effect is achieved.

Discussion

Smoking is not only a physical dependence, but also a psychological dependence, thus, smoking cessation requires more than a strong will [21]. This study can only be carried out when the participants have certain intentions to quit smoking. We will choose two methods of NRT and acupuncture for the combined intervention of smokers who are willing to quit. Acupuncture is a relatively common and effective method in traditional Chinese medicine, while NRT is the most commonly used of the internationally recognized interventions. This combination is rarely reported in the literature, and it is expected to achieve better outcomes. We know that smoking behavior falls under the category of "mental and behavioral disorders resulting from the use of psychoactive substances" [22]. Thus, the choice of control group will not be a single intervention, but a combination of a placebo treatment of another method, as well as a group of pure placebo group. Each group will receive two interventions designed to blind the participants and provide a psychological cue that will help improve the effect of the intervention and promote participant compliance with the regulations.

There is a paradigm shift towards patient-centered care and active involvement of participants and public in research design and active participation throughout the research process [23]. However, to ensure the implementation of blind method in the later stage of the experiment, this paradigm has not adopted in the design of this study, and the protocol designers will be all composed of trial researchers, without the participation of the public or participants.

There are several limitations in the current study. First, although we chose the double dummy to try to blind the study participants, we are unable to blind the physicians, which may lead to some bias. However, all the subjective indicators are collected through the network background, which will minimize these biases to some extent. Secondly, although we have performed the sample size calculation, the sample size is still small, and a large sample test will be needed in the future stage.

Our study will evaluate the efficacy and safety of different interventions for smoking cessation, providing some evidence for smokers to choose smoking cessation programs, as well as for future studies, and promote the development of acupuncture for smoking cessation. The results will be published within 6 months after the trial completed.

Trial status

The study registration number is ChicTR2100042912, and the recruitment is still ongoing. Recruitment may end in October 2020.

Abbreviations

ACNP: Acupuncture combined with nicotine patch; ACSNP: Acupuncture combined with sham nicotine patch; SACNP: Sham acupuncture combined with nicotine patch; SACSNP: Sham acupuncture combined with sham nicotine patch; FTND: Fagerstrom test for nicotine dependence; MNWS: Minnesota

Page 7 of 8

Nicotine Withdrawal Scale; QSU-Brief: The Brief Questionnaire of Smoking Urge; SNK: Student-Newman-Keuls.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13063-022-06384-9.

Supplementary file 1. SPIRIT Checklist for Trials.

Acknowledgements

We are grateful to Xingke Yan and Yanfeng Zhang, The College of Acupuncture-Moxibustion and Tuina, Gansu University of Chinese Medicine, Bei Xu and Haiying Yao, Gansu Gem Flower Hospital, and all the staffs who assisted in recruiting. We appreciate the contribution from all the participants in the trial.

Auditing

There is no audit plan.

Protocol amendment

If there are major changes to the trial protocol, we will issue a written description of formal clarification.

Dissemination policy

Published within 6 months of trial completion.

Authors' contributions

QSW, RJD, HLZ, XMJ, XJM, XRZ, SSB, DR, and JCF have all contributed to the development of the research protocol. RJD, HLZ, XJM, XRZ, and JCF participated in the registration of the trial. JCF, DR, and XMJ conceived the trial and provided methodological advice, while the QSW, RJD, and SSB were involved in the design of the statistical analysis. QSW and RJD wrote the manuscript; JCF and SSB revised and polished it. All authors read and approved the final version.

Funding

This study is supported by the Talent Introduction Program of Gansu University of Chinese Medicine [grant number 2016YJRC-01], the Second Batch of Science and Technology Projects from Chengguan District, Lanzhou, Gansu Province, China [grant number 2020-2-11-16], and the University Innovation Capacity Improvement Project in Gansu Province. Sponsor and funders have no further role in the study design; data collection, management, analysis, or interpretation of data; writing reports; or the decision to submit a report for publication.

Declarations

Ethics approval and consent to participate

This study has been approved by the Ethics Committee of the Affiliated Hospital of Gansu University of Chinese Medicine, including consent form, patient information form, and questionnaire (Approval No. 20203). In order to participate in the study, participants must give informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Clinical College of Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, People's Republic of China. ²Pneumology Department, Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, People's Republic of China. ³School of Public Health, Laboratory and Simulation Training Center, Center for Evidence-Based Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, People's Republic of China. ⁴Psychosomatic and Sleep Medicine, Gansu Gem Flower Hospital, Lanzhou, Gansu 730060, People's Republic of China. ⁵Health Center of Hekou Town, Xigu District, Lanzhou, Gansu 730060, People's Republic of China.

Received: 6 August 2021 Accepted: 7 May 2022 Published online: 06 June 2022

References

- World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: diagnostic criteria for research. Clinical Descriptions & Diagnostic Guidelines Geneva. 1993. https://www.mendeley. com/catalogue/19782f27-db9a-3f14-a2af-10aa58fb500b/
- Botvin GJ. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. U.S. National Library of Medicine; 2014. https://stacks.cdc.gov/view/cdc/21569.
- Qin YB, Qu NN, Zheng X, et al. Clinical observation of Chinese herbal quit smoking Babu Patch combining acupuncture treating tobacco dependence with phlegm and blood stasis syndrome. Chin J Tradit Chin Med and Pharm. 2020;35(11):542–6.
- Bloom EL, Minami H, Brown RA, et al. Quality of life after quitting smoking and initiating aerobic exercise. Psychol Health Med. 2017;22(9):1127–35. https://doi.org/10.1080/13548506.2017.1282159.
- Toll BA, Rojewski AM, Duncan LR, et al. "Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. Clin Cancer Res. 2014;20(2):301–9. https://doi.org/10.1158/ 1078-0432.CCR-13-2261.
- D'Argenzio A, D'Argenio P, Ferrante G, et al. 40% of smokers try to stop smoking, only 8% succeed in. Epidemiol Prev. 2011;35(5-6):362.
- Jang S, Lee JA, Jang BH, et al. Clinical effectiveness of traditional and complementary medicine interventions in combination with nicotine replacement therapy on smoking cessation: a randomized controlled pilot trial. J Altern Complement Med. 2019;25(5):526–34. https://doi.org/ 10.1089/acm.2019.0009.
- Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5(5):Cd000146. https://doi.org/10.1002/14651858.CD000146.pub5.
- Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine Polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 1999;159(17):2033–8. https://doi.org/10.1001/archinte.159.17.2033.
- Vogeler T, McClain C, Evoy KE. Combination bupropion SR and varenicline for smoking cessation: a systematic review. Am J Drug Alcohol Abuse. 2016;42(2):129–39. https://doi.org/10.3109/00952990.2015.1117480.
- 11. Guo ST, Lin H, Chi JF. Recent advances in the methods for smoking cessation. Chin Gen Pract. 2017;30:117–21.
- Chai X, Yang JS, Liu Z, et al. Effect of the different smoking cessation regimens with acupuncture on smoking withdrawal and their influence factors: a multi-center randomized controlled trial. Zhongguo Zhen Jiu. 2019;39(12):1255–61. https://doi.org/10.13703/j.0255-2930.2019.12.001.
- Wang YY, Liu Z, Wu Y, et al. Efficacy of acupuncture is noninferior to nicotine replacement therapy for tobacco cessation: results of a prospective, randomized, active-controlled open-label trial. Chest. 2018;153(3):680–8. https://doi.org/10.1016/j.chest.2017.11.015.
- 14. Hyun S, Huh H, Kang NG. Effectiveness of auricular acupuncture combined with nicotine replacement therapy for smoking cessation. Tob Induc Dis. 2018;16(40). https://doi.org/10.18332/tid/94328.
- Lhommeau N, Huchet A, Castera P. Acupuncture and smoking cessation, a review of the literature. Rev Mal Respir. 2020;37(6):474–8. https://doi. org/10.1016/j.rmr.2020.02.016.
- Dai R, Cao Y, Zhang H, et al. Comparison between acupuncture and nicotine replacement therapies for smoking cessation based on randomized controlled trials: a systematic review and bayesian network meta-analysis. Evid Based Complement Alternat Med. 2021;2021:9997516. https://doi. org/10.1155/2021/9997516.
- Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. https:// doi.org/10.1136/bmj.e7586.
- Wang YY, Liu Z, Wu Y, et al. A randomized controlled trial on smoking cessation by acupuncture. J Beijing Univ Tradit Chin Med. 2018;v.41(07):79–84.

- Wang M, Luo X, Xu S, et al. Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013. Lancet Respir Med. 2019;7(1):35–45. https://doi.org/10. 1016/S2213-2600(18)30432-6.
- Parker L, Mok MS. The use of acupuncture for smoking withdrawal. Am J Acupunct. 1977;5(4):363–6.
- Sammito S, Claus A, Rose DM. Smoking prevalence in the area of responsibility of the German Ministry of Defense - results of the employee survey in the context of occupational health management. Mil Med Res. 2020;7(1):5.
- 22. World Health Organization. International classification of diseases, 10th revision, online versions. 2016.
- Neo HY. From Bolam-Bolitho to modified-montgomery a paradigm shift in the legal standard of determining medical negligence in Singapore. Ann Acad Med Singapore. 2017;46(9):347–50.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

